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A NEW GOVERNANCE APPROACH TO REGULATING HUMAN
GENOME EDITING
John M. Conley, Arlene M. Davis, Gail E. Henderson, Eric T.
Juengst, Karen M. Meagher, Rebecca L. Walker, Margaret
Waltz, & Jean Cadigan∗
For years, genomic medicine—medicine based on the growing
understanding of the genetic contribution to many diseases and
conditions—has been hailed as the future of medical treatment, but
it has thus far had limited effect on day-to-day medical practice.
The ultimate goal of genomic medicine has always been the ability
not just to identify dangerous gene mutations, but to fix them. Now
CRISPR and related genome-editing technologies may have the
potential to provide a safe and effective way to repair dangerous
mutations.
In the wake of ethically dubious experiments with human
embryos in China, the international governance of human genome
editing is emerging as an urgent topic for scientists, regulators,
and the public. Efforts to develop a governance model are
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underway at national and international levels. These efforts are the
subject of multiple initiatives by national and international health
and science organizations and are topics of discussion at scientific
conferences, summits, and meetings.
This Article reports on the Authors’ multi-year,
interdisciplinary project to identify and investigate the practical,
ethical, and policy considerations that are emerging as the
greatest concerns about human genome editing, and ultimately to
develop policy options. The project involves monitoring the
discussions of groups, both government-sponsored and private,
that are considering how genome editing should be governed;
observing conferences where the topic is discussed; analyzing
emerging policy reports by national and international bodies; and
interviewing a wide range of stakeholders, including scientists,
ethicists, and those who make and comment on public policy. The
Article identifies several stakeholder concerns that are especially
prominent in the research to date and begins to explore the
implications of these concerns for alternative models of governance.
There are current indications that, for practical purposes, a focus on
“soft,” hybrid forms of governance based on networks of multiple
public and private stakeholders may turn out to be the most
promising course to pursue. The “new governance” paradigm
developed in the corporate and financial sectors offers a useful
model for understanding the dynamics of this approach.
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I. INTRODUCTION
The first reports of human genome editing—altering the
genetic code of a human being—in nonviable embryos in China in
2015 ignited a wave of ongoing policy discussions about the
appropriate limits of such research in today’s globalized scientific
environment.1 Chinese scientist He Jiankui’s 2018 claim to have
edited the embryonic genome of living twin baby girls2 (for which
he was reportedly imprisoned for “illegal medical practices”),3
followed by a Russian geneticist’s announcement of similar plans,4
1

See Carolyn Brokowski, Do CRISPR Germline Ethics Statements Cut It?, 1 CRISPR
J. 115, 115–23 (2018), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694771/
[https://perma.cc/WYQ9-CTN6].
2
Dennis Normile, CRISPR Bombshell: Chinese Researcher Claims to
Have
Created
Gene-Edited
Twins,
SCI. (Nov. 26,
2018),
https://www.sciencemag.org/news/2018/11/crispr-bombshell-chinese-researcherclaims-have-created-gene-edited-twins [https://perma.cc/JYC7-DSH9].
3
Dennis Normile, Chinese Scientist Who Produced Genetically Altered
Babies Sentenced to 3 Years in Jail, SCI. (Dec. 30, 2019),
https://www.sciencemag.org/news/2019/12/chinese-scientist-who-producedgenetically-altered-babies-sentenced-3-years-jail [https://perma.cc/7FCZ-QT2B].
4
See Jon Cohen, Embattled Russian Scientist Sharpens Plans to Create
Gene-Edited
Babies,
SCI.
(OCT.
21,
2019),
https://www.sciencemag.org/news/2019/10/embattled-russian-scientistsharpens-plans-create-gene-edited-babies [https://perma.cc/B5M9-GPTC]. The
Russian scientist has not abandoned his plans, even after the controversy in
China. See Michael LePage, Russian Scientist Still Aims to Make CRISPR
Babies Despite the Risks, NEW SCIENTIST (Sept. 3, 2020),
https://www.newscientist.com/article/2253688-russian-biologist-still-aims-tomake-crispr-babies-despite-the-risks/ [https://perma.cc/FWM8-4A63].
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gave new urgency to those discussions.5 Current human genome
editing governance consists of a patchwork of national, local, and
institutional regulations and scientific and professional policy
statements; some of those statements aim at international status,
but few offer specific prescriptions for oversight.6 In the wake of
the developments in China, efforts to harmonize this patchwork
across jurisdictions and stakeholder groups have been the topic of
multiple conferences, declarations, and publications, involving
both scientists and policymakers.
The Authors are engaged in a multi-year, interdisciplinary
project to identify and investigate the practical, ethical, and policy
considerations that are emerging as the greatest concerns about
human genome editing, and ultimately to develop policy options
for governance of this rapidly evolving science. The project uses
the term governance rather than such alternatives as “government,”
“regulation,” or “control” in order to be open to all oversight
possibilities, in whatever form and from all possible sources of
authority or influence. The project involves, among other research,
monitoring the publicly accessible discussions of groups, both
government-sponsored and private, that are considering how
genome editing should be governed; observing conferences where
the topic is discussed; analyzing emerging policy reports by
national and international bodies; and interviewing a wide range of
stakeholders, including scientists, ethicists, and those who make
and comment on public policy. This Article identifies several
stakeholder concerns that are especially prominent in the research
to date and begins to explore the implications of these concerns for
alternative models of governance. There are current indications
that, for practical purposes, a focus on “soft,” hybrid forms of
governance based on networks of multiple public and private
stakeholders may turn out to be the most promising course to
pursue.7 The “new governance” paradigm developed in the
5

See Henry T. Greely, He Jiankui, Embryo Editing, CCR5, the London
Patient, and Jumping to Conclusions, STAT (Apr. 15, 2019),
https://www.statnews.com/2019/04/15/jiankui-embryo-editing-ccr5/ [https://per
ma.cc/HTU3-R7XT].
6
See Brokowski, supra note 1.
7
See infra Part VI.C.
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corporate and financial sectors offers a useful model for
understanding the dynamics of this approach.8
Part II of the Article describes the basic science of genome
editing. Part III explains the various categories of genome editing
and the need for governance across these categories. Part IV
presents the research project in more detail and reports some of its
significant findings to date. Part V uses these findings to analyze
the possible approaches to genome editing governance that are
being proposed, with specific reference to the concerns that seem
to be motivating the various proposals. Part VI evaluates each
approach in terms of its potential to meet these concerns, and Part
VII offers a brief conclusion.
II. GENOME EDITING TECHNOLOGY
A. Genes and the Genome
An organism’s genome is the entirety of the DNA in its cells.9
Genes are the subset of the genome that perform the function of
building, or coding for, proteins.10 The details of the
protein-building function depend on the specific DNA that is
present in the organism’s cells. DNA, the chemical responsible for
inheritance, is a double-stranded molecule containing long strings
of four chemicals called bases (abbreviated A, T, C, and G);
because DNA is double-stranded, they appear as base pairs, one on
each strand. The order of the base pairs in an organism’s genome is
its DNA sequence. It is this sequence that determines what proteins
an organism’s cells build, and when. Genes account for only a
8

See generally John M. Conley & Cynthia A. Williams, Global Banks as
Global Sustainability Regulators?: The Equator Principles, 33 J.L. & POL’Y 542
(2011) (presenting case study of new governance approach to global banking
problem).
9
The brief overview of genome editing in this section is based on John M.
Conley, Introduction: A Lawyer’s Guide to Crispr, 97 N.C. L. REV. 1041, 1042–
47 (2019). Readers interested in more detail about the underlying science should
consult that reference and the sources cited therein.
10
The distinction between genome and genes, and thus between genome
editing and gene editing, is important to scientists but rarely of interest to other
audiences. The policy literature tends to use genome and gene editing
interchangeably, as the authors do on occasion in this Article.
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small portion of the DNA in the genome.11 Other portions of the
genome have regulatory functions, such as controlling when
particular genes switch on and off, while other large portions of the
genome have no currently known function.12 RNA is a
single-stranded cousin of DNA that performs many functions in
the cell.13 By coding for proteins in particular ways, DNA provides
a template for life; it determines the identities of different species,
and influences some of the differences between individuals within
a species. Some DNA variants, or mutations—changes in the
sequence from the organism’s usual pattern—can contribute to, or,
in some cases, cause a disease or disability. Still, other variants
may be beneficial in the sense offering special protections from
disease or disability.
B. CRISPR Gene Editing
To edit the genome is to intervene in a cell and change its
DNA sequence. This can be done in a variety of ways: by excising
one or more bases, by turning particular bases on or off, or even by
substituting one sequence for another. This latter possibility
represents the ultimate promise of genomic medicine: the ability
not just to identify dangerous gene mutations, but to fix them, to go
into a patient’s cells and change a dangerous DNA sequence to a
non-pathogenic one.
Gene editing technologies have been around for more than
twenty-five years. Earlier approaches include Zinc-Finger
Nucleases (ZFNs) and Transcription Activator-Like Effector
Nucleases (TALENs).14 The current focus is on a technology called
CRISPR, which stands for Clustered Regularly Interspaced

11
See Jonathan Henninger, The 99 Percent . . . of the Human Genome, HARV.
UNIV.: SCI. IN THE NEWS (Oct. 1, 2012), http://sitn.hms.harvard.edu/
flash/2012/issue127a/ [https://perma.cc/ECM6-4HV9].
12
See id.
13
See Carl Zimmer, Breakthrough DNA Editor Born of Bacteria, QUANTA
MAG. (Feb. 6, 2015), https://www.quantamagazine.org/crispr-natural-history-inbacteria-20150206/ [https://perma.cc/3Q9J-D2CE].
14
See Conley, supra note 9, at 1046.
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Palindromic Repeats.15 These are short repeating sequences in the
DNA of E. coli and other bacteria that were discovered by
Japanese researchers in the 1980s.16 Their function was unknown
for about twenty years, until food scientists using bacteria to make
yogurt figured out that they are part of the bacteria’s immune
system.17 These scientists realized that the CRISPR sequences
resemble the DNA of viruses.18 In fact, the CRISPR sequences are
taken from viral DNA that the bacteria has captured during past
viral invasions.19 When a new viral attack occurs, the bacteria’s
immune system compares the virus’s genetic material to the
sequences stored in CRISPR; if it detects a match, it launches
enzymes (a class of proteins that facilitate chemical reactions) to
cut up the incoming viral DNA and repel the invasion.20
The bacterial CRISPR sequences are always accompanied by
genes that code for enzymes that can cut DNA.21 The original
CRISPR scientists called them Cas (for CRISPR-associated)
genes.22 Later research revealed that when viruses invade a
bacterial cell, the CRISPR regions produce single-stranded RNA
versions of the viral DNA sequences that it has captured and
stored.23 These RNA sequences are cradled by the Cas enzymes
and carried around the cell.24 When an RNA sequence encounters
its viral DNA counterpart it latches on and the Cas enzyme cuts the
DNA, which stops the virus from replicating.25
Current CRISPR gene-editing technology mimics this natural
process. Researchers at the University of California-Berkeley
15

Brad Plumer et al., A Simple Guide to CRISPR, One of the Biggest
Science
Stories
of
the
Decade,
VOX
(Dec.
27,
2018),
https://www.vox.com/2018/7/23/17594864/crispr-cas9-gene-editing
[https://perma.cc/N6AM-MBMA].
16
Id.
17
Id.
18
Id.
19
Id.
20
Id.
21
Plumer et al., supra note 15.
22
Id.
23
Id.
24
Id.
25
Id.
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chose a pair of Cas enzymes called Cas9.26 They supplied the
enzymes with the RNA counterpart of the genetic sequence they
wanted to edit—the target gene.27 The RNA finds and binds to the
target DNA and the Cas9 enzymes cut it at its two ends.28 With the
target gene excised, the cell can be induced to make a new one.29 In
the simplest application, the CRISPR mechanism finds and cuts
out a “defective” gene—for example, one that causes a single-gene
disease such as cystic fibrosis, hemophilia, or sickle cell disease—
and the cell replaces it with a normal one.30 CRISPR technology
can also be used to introduce a new gene into the space.31
CRISPR represents a major advance over previous editing
technologies in terms of efficiency and accuracy.32 CRISPR was
used in the ethically contentious Chinese experiments and is now a
primary tool in a global research effort, with projects ranging from
basic science to plant and animal research to early efforts to apply
it in human medicine. To illustrate, a recent survey of published
CRISPR developments by a Spanish research institute lists the
correction of a gene responsible for Duchenne muscular dystrophy
in humans and mice, and—all in mouse models—improvements in
progeria (premature aging disease), correction of a gene that causes
obesity, and the development of a new cancer strategy that uses
CRISPR and immunotherapy (stimulating the body’s natural
defenses).33 Similarly, at a July 2020 virtual conference of genome
editing scientists, industry representatives, and government
regulators organized by the Genome Writers Guild, a

26

Plumer et al., supra note 15.
Id.
28
Id.
29
Id.
30
Id.
31
See Zimmer, supra note 13.
32
See Conley, supra note 9, at 1047.
33
Lucia Gomez-Tatay, CRISPR Promises: Some of the Most Recent
Developments in Gene Editing, BIOETHICS OBSERVATORY (Feb. 4, 2020),
https://bioethicsobservatory.org/2020/02/crispr-promises-some-of-the-most-recentadvances-in-gene-thera/34049/?at_a_glance_summer_issue [https://perma.cc/NQ69NR95].
27
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self-described “genome engineering society”34 (which members of
the research group attended), the use of CRISPR was discussed in
sessions on animal and plant editing developments, editing repair,
gene and cell therapies, many of which are now in human use, and
the use of oncolytic (cancer-cell-killing) viruses.35
A final and highly important technical point is the distinction
between germline and somatic cell editing. The genetic information
in somatic cells—the cells that make up nonreproductive organs and
tissues—cannot be passed down to future generations. Germline
cells are the reproductive cells (eggs and sperm) in adults, which
do pass along parental genetic information, and the cells in
undifferentiated early embryos, which provide the genetic
instructions for all the subsequent cells in the body, including the
reproductive cells. Thus, germline edits, like natural mutations, are
transmitted to future generations. For this reason, while concerns
about editing somatic cells are focused on the individual patient,
germline edits also raise concerns for future generations.
III. THE CATEGORIES OF GENOME EDITING AND THE NEED FOR
GOVERNANCE
As noted above, current genome-editing governance is, at
most, a patchwork of national and local laws, many of which apply
only by implication, together with initiatives of many advisory and
advocacy groups.36 Across this patchwork, one widespread point of
early consensus is that gene editing research should prioritize
medical applications over attempts to enhance human traits, given
the moral concerns—such as exacerbating background social
injustices—the latter would raise.37 Underlying this consensus is a
broadly accepted distinction between gene editing for treatment or
prevention of disease and disability, on the one hand, and

34
GENOME WRITERS GUILD, https://www.genomewritersguild.org/
[https://perma.cc/59YQ-YFDM].
35
GWG 2020 Conference Program, GENOME WRITERS GUILD,
https://www.genomewritersguild.org/gwgcon2020program [https://perma.cc/FU97Z8FD].
36
See Brokowski, supra note 1 and accompanying text.
37
See Brokowski, supra note 1.
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enhancement of traits generally regarded as “normal,” on the
other.38
On the whole, genetics professionals39 and the public40 seem to
concur with this consensus. However, some policy statements have
expanded the definition of “medical applications” beyond the
categories of disease treatment or prevention, further complicating
the issue.41 Moreover, few of the policy initiatives have offered
specific suggestions for how science policy should deal with
research governance issues.
Other forms of biomedical enhancement already illuminate
multiple ways in which using human gene editing to prevent
disease could open the door to enhancement applications. For
example, compensatory enhancements like immunizations
intentionally strengthen particular human functions beyond a
typical baseline in order to counteract pathogenic threats.42 They
are generally not controversial, but can become so if used in such
38

The consensus about this distinction has its origins in the governance of
pre-gene editing human gene therapy. See generally Eric Juengst, The NIH
“Points to Consider” and the Limits of Human Gene Therapy, 1 HUMAN GENE
THERAPY 425 (1990); Eric Juengst & LeRoy Walters, Ethical Issues in Human
Gene Transfer Research, THE DEVELOPMENT OF HUMAN GENE THERAPY 691,
691–713 (Theodore Friedmann ed., 1999) (both sources illustrating the
development of the consensus in the pre-gene editing environment).
39
See Alyssa Armsby et al., Survey Results: Genetics Specialists’ Views on
Genome Editing, EUREKALERT (Oct. 19, 2017), https://www.eurekalert.org/
pub_releases/2017-10/asoh-srg101117.php [https://perma.cc/6WF3-FQD7].
40
See U.S. Public Opinion on the Future Use of Gene Editing, PEW RSCH.
CTR. (July 26, 2016), https://www.pewresearch.org/science/2016/07/26/u-s-publicopinion-on-the-future-use-of-gene-editing/ [https://perma.cc/VY6U-TY6X].
41
See generally, e.g., NETHERLANDS COMM’N ON GENETIC MODIFICATION,
EDITING HUMAN DNA: MORAL AND SOCIAL IMPLICATIONS OF GERMLINE
GENETIC MODIFICATION (2017), https://cogem.net/app/uploads/2019/07/GermlineModification1.pdf [https://perma.cc/R35E-T88E]; Genome Editing and Human
Reproduction: Social and Ethical, NUFFIELD COUNCIL ON BIOETHICS (2018),
https://www.nuffieldbioethics.org/publications/genome-editing-and-humanreproduction [https://perma.cc/VK5K-FGKV] (both sources reflecting an
expanded definition of “medical” applications).
42
See Anita Silvers, Meliorism at the Millennium: Positive Molecular
Eugenics and the Promise of Progress without Excess, in MUTATING CONCEPTS,
EVOLVING DISCIPLINES: GENETICS, MEDICINE, AND SOCIETY 215–34 (L.S.
Parker & Rachel A. Ankeny eds., 2002).
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practices as the U.S. military’s efforts to produce a
“[m]etabolically [d]ominant [s]oldier” who can go “for days with
little or no food[.]”43 Another category, secondary enhancements,
is illustrated by the efforts of biogerontologists to develop ways of
controlling human senescence in order to prevent late-life
diseases.44 Once again, the basic uses are noncontroversial, but
those efforts could also extend the healthy human life span beyond
its historical limits, raising concerns about the value of the
traditional human life cycle.45 In other cases, interventions that
could forestall disease in at-risk patients might also be used
off-label to enhance functional traits in healthy individuals.46 For
example, synthetic human growth hormone was developed to help
prevent extreme short stature due to hormonal deficiencies, but
ethical questions arose about its use to enhance the height of
hormonally typical young people.47 Finally, interventions designed
to enhance particular traits are sometimes rationalized as
therapeutic or preventive—that is, medicalized—in order to justify
their development as biomedical tools; the medical rationale for
purely cosmetic breast enhancement surgery is a classic example.48
43

See William Matthews, Supersoldiers: Can Science and Technology
Deliver Better Performance?, ARMY MAG. (Apr. 20, 2015),
https://www.ausa.org/articles/supersoldiers-can-science-and-technology-deliverbetter-performance [https://perma.cc/7G7P-DQ39].
44
See James L. Kirkland, The Biology of Senescence: Potential for Prevention
of Disease, 18 CLINICS GERIATRIC MED. 383, 394 (2002).
45
See generally A WORLD GROWING OLD: THE COMING HEALTH CARE
CHALLENGES (DANIEL CALLAHAN, RUUD H. J. TER MEULEN & EVA TOPINKOVÁ
EDS., 1995) (describing the cross-disciplinary challenges and issues of an aging
population).
46
For a discussion of this issue in a non-genetic context, see Lisa E. Smilan,
The Off-Label Loophole in the Psychopharmacologic Setting: Prescription of
Antipsychotic Drugs in the Nonpsychotic Patient Population, 30 HEALTH
MATRIX: THE J. OF L. MED. 233 (2020).
47
See SHEILA M. ROTHMAN & DAVID J. ROTHMAN, THE PURSUIT OF
PERFECTION: THE PROMISE AND PERILS OF MEDICAL ENHANCEMENT 16–17
(2003). Ethical questions have also been raised about the use of growth hormone
to prevent extreme short stature because of the normative implications of
“heightism.” In that case, however, the concern is less with enhancement than
with the underlying social norms themselves.
48
See Linda F. Hogle, Enhancement Technologies and the Body, 34 ANN.
REV. ANTHROPOLOGY 695, 700 (2005).
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Since the 1980s, bioethicists have used cases of enhancement
like these to mount or refute arguments about whether
enhancement interventions can ever be meaningfully distinguished
from medical applications.49 They have asked whether these cases
raise any moral concerns,50 and what societal responses they
warrant.51 But however one resolves these ethical debates, they
leave unanswered another question at the level of research
governance: even if stakeholders generally accept both the
conventional treatment-enhancement boundary and the endorsement
of prevention as a legitimate goal for gene editing, how should
governance policy deal with the resulting incidental enhancement
concerns? More specifically, how should policymakers deal with
apparent enhancements that are unintended side effects—“off-label”
uses that are compensatory in one context but not in another—or
otherwise tread the line between prevention, treatment, and
enhancement? To answer this, those engaged in developing
responsible governance for gene editing research need to know
more about the contexts of this research, the moral meaning of
enhancement in those contexts, and its salience as a boundary
marker for gene editing research. It is to such issues that the
research project and this Article are addressed.
IV. THE RESEARCH PROJECT
The Authors began their collaborative research in 2018, and in
May 2020 they received a four-year grant from the National
Human Genome Research Institute (part of the National Institutes
of Health) to support an intensive, multidisciplinary research
effort.52 The research group’s members come from bioethics,
49

See Eric T. Juengst, Can Enhancement Be Distinguished from Prevention in
Genetic Medicine?, 22 J. MED. & PHIL. 12, 134–36 (1997).
50
See JOHANNN A.R. RODUIT, THE CASE FOR PERFECTION: ETHICS IN THE AGE
OF HUMAN ENHANCEMENT 71–86 (2016).
51
See MAXWELL J. MEHLMAN, THE PRICE OF PERFECTION: INDIVIDUALISM
AND SOCIETY IN THE ERA OF BIOMEDICAL ENHANCEMENT 185–210 (2009).
52
Project Information: 1R01HG010661-01A1, NAT’L INST. HEALTH,
https://projectreporter.nih.gov/project_info_description.cfm?aid=9967484&icde
=52225919&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pbal
l= [https://perma.cc/AZ7A-MTN7] (last visited Nov. 2, 2020).
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anthropology, sociology, law, philosophy, and public policy. A
major component of the method is ethnographic, relying on
interviews, participant observation at relevant events, and
monitoring the public activities of governmental bodies and
nongovernmental interest groups. The research also includes
ongoing Internet and literature research and policy analysis.
In order to ground the project’s understanding of the critical
ethical and policy issues in a scientific perspective, the researchers
have begun to identify and interview scientists whose work is
relevant to gene editing. They are identifying scientists through
monitoring the emerging literature as well as websites, email
listservs, and other online sources; participant observation53 at
conferences and meetings; opportunistic follow-up with colleagues
and associates of people being interviewed; and consultation with a
group of global advisors to the project. Using both quantitative and
qualitative interpretive analytical methods, the research group is
seeking to identify the conceptual points, ethical arguments, and
policy considerations that are emerging as the greatest concerns in
the scientific community.
At the same time, the research is also focusing on groups that
are beginning to consider how gene editing should be governed.
These include government-sponsored organizations such as the
National Academies of Sciences, Engineering, and Medicine’s
Human Genome Editing Initiative in the United States and its
international counterparts;54 government-sponsored international
groups such as the World Health Organization;55 and private,
voluntary groups advocating for various kinds of self-governance,
such as the Association for Responsible Research and Innovation

53

Participant observation is an anthropological method. As the phrase
suggests, it involves immersing oneself to the maximum extent possible in the
activities of the group being studied, simultaneously observing and participating
in those activities. For a fuller explanation and an example of the method
used in another bioethical context, see John M. Conley et al., Is Real-Time
ELSI Realistic?, 11 AM. J. B IOETHICS EMPIRICAL 134, 136–37 (2020),
https://doi.org/10.1080/23294515.2020.1722289 [https://perma.cc/AD9E-KEUY].
54
See infra notes 64–72 and accompanying text.
55
See infra notes 78–79, 129–31 and accompanying text.
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in Genome Editing (ARRIGE) and the Genome Writers Guild.56
For such groups, the researchers are collecting relevant
information from websites, published documents, and listserv
emails; and engaging participant observation of their meetings and
conferences. In the analysis of their respective views and
approaches, the primary focus is on governance proposals relevant
to the scientific issues identified above. The project’s ultimate
objective is to develop useful guidance for governance that is
particularly attentive to the policy trade-offs between preventive
benefits and enhancement concerns.
In the sections that follow, the Authors outline some of the
major themes that are emerging in the research to date and map
these themes onto some of the relevant governance literatures. The
Article concludes with some preliminary recommendations about
policy.
V. APPROACHES TO GOVERNING HUMAN GENOME EDITING
RESEARCH
In the relevant literatures and the project’s research to date,
governance discussions have centered on some combination of
four basic approaches to regulating or guiding gene editing
research. One possibility is self-regulation, in this case by the
scientific community—the loosely connected network of scientists
who are working, directly or indirectly, on genome editing and its
applications. Self-regulation can rely on nothing more than
advisory or aspirational ethical codes or—as in the case of the
traditional professions like medicine or law—can involve the
authority, delegated by government, to create barriers to entry
(licensing requirements, for example) and discipline noncompliant
members. Two other approaches involve “hard” regulation,
defined as rules of law imposed by and enforceable by
governments. The imposition of hard regulation can take place at
the level of the individual nation-state or at the international level.
In the latter case, national governments, usually acting by treaty,
can imbue an existing supranational organization with regulatory
power or create a new one for a specific purpose. As the Authors
56

See infra notes 74–76, 99–100 and accompanying text.
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will argue, the success of any international regime always comes
down to the will of the participating states. The last approach is a
hybrid. Called variously soft, polycentric, anticipatory, or new
governance (perhaps the most widely used term, which this Article
uses), its hallmark is a diffusion of rights and responsibilities among
networks of state and non-state stakeholders—governments,
corporations, non-governmental organizations (“NGOs”), and
others—that transcend national boundaries.
In the presentation and discussion of these governance
approaches in the ongoing wave of declarations and reports on
human genome editing, three sets of stakeholder concerns emerge
as particularly prominent: (1) threats to the gene editing scientific
community’s privileged standing as a self-governing professional
community; (2) worries about developing hard forms of
governance having the force of law at the international level; and
(3) anxieties about public support for, and trust in, the human
genome editing research enterprise. When these concerns are
mapped onto each of the main governance approaches, the reasons
for its widespread endorsement as an approach to gene editing
governance become apparent.
A. Threats to Scientific Self-Governance
Genome scientists, like other technical experts and
members of traditional professions, have enjoyed wide latitude in
governing their own work in exchange for voluntary adherence to
expected norms of behavior.57 The rationale for this “grand bargain”
between science and society is that socially beneficial knowledge is
produced and applied more efficiently if scientists are granted
professional autonomy.58 That model is under pressure today,
however, as the professional role of scientists in high-income
countries becomes more market-oriented.59 At the same time,
57
For an early overview, see ANDREW ABBOTT, THE SYSTEM OF
PROFESSIONS: AN ESSAY ON THE DIVISION OF EXPERT LABOR (1988).
58
The “grand bargain” theory is explained and criticized in RICHARD
SUSSKIND & DANIEL SUSSKIND, THE FUTURE OF THE PROFESSIONS: HOW
TECHNOLOGY WILL TRANSFORM THE WORK OF HUMAN EXPERTS 9–45 (2015).
59
As evidence of this shift, one need to look no further than the proliferation of
technology transfer offices in U.S. universities, designed in part to help university
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especially in China, the alleged role of scientists as agents of the
state presses the grand bargain model from the other direction,
raising concerns about nationalistic influences on research.60
Concerns about threats to scientific self-governance have
emerged in the discussion of human genome editing since the
initial calls for moratoria on human germline interventions by
groups of individual scientists.61 Thus, some prominent senior
scientists who were active in recombinant DNA research in the
1970s have tried to frame the current debate as one best managed
by the scientific community itself.62 They sometimes invoke the
iconic 1974 Asilomar Conference, where scientists, physicians,
and lawyers discussed the potential risks of early recombinant
DNA technology and produced a set of voluntary guidelines.63
These concerns have also surfaced in the initiatives organized
by national science academies. For example, the revelation of
human embryo editing experiments in China came just before the
2018 Second International Summit on Human Gene Editing in
Hong Kong, which was sponsored by the U.S. National Academies
of Science, Engineering and Medicine (NASEM) and its
counterparts in the U.K. and Hong Kong.64 He Jiankui, the Chinese
scientist who conducted those experiments, had been scheduled to

scientists bring their invention to the for-profit private sector. At UNC-CH, for
example, this office is called the Office of Technology Commercialization. UNC
OFFICE OF TECH. COMMERCIALIZATION, https://otc.unc.edu/ [https://perma.cc/P5BX7ED6] (last visited Oct. 13, 2020).
60
See, e.g., Nidhi Subbaraman, US Investigations of Chinese Scientists Expand
Focus to Military Ties, NATURE (2020), https://www.nature.com/articles/d41586-02002515-x [https://perma.cc/PBK3-8W3D].
61
See infra note 76 and accompanying text.
62
See, e.g., Comm. on Sci., Tech., & L. Pol’y & Glob. Affairs, International
Summit on Human Gene Editing: A Global Discussion, NAT’L ACADS. PRESS 4–6
(Dec. 1–3, 2015), https://www.nap.edu/read/21913/chapter/1 [https://perma.cc/SH9R279M].
63
See e.g., Paul Berg et al., Summary Statement of the Asilomar Conference
on Recombinant DNA Molecules, 72 PROC. NAT’L. ACADS. SCI. 1981 (1975).
64
See Nat’l Acads. of Sci., Eng’g, & Med., Second International Summit on
Human Genome Editing: Continuing the Global Discussion, NAT’L ACADS. PRESS
(Jan. 10, 2019), https://www.nap.edu/read/25343/chapter/1 [https://perma.cc/K8UVAYT4].
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speak on different work.65 When the embryo editing came to light,
He was given his own session, which played out amid great tension
and critical questioning from the audience.66 In the aftermath of
this drama, the organizing committee nonetheless put out a
statement that attempted to straddle the line between regulation
and scientific freedom. On the one hand, it labeled the human
germline genome-editing experiments as “unexpected and deeply
disturbing,” with “flaws” ranging from study design to “failure to
meet ethical standards,” echoing a rogue science theme; on the
other hand, it defended professional autonomy by arguing for the
creation of “a rigorous, responsible translational pathway toward
[germline genome-editing] trials.”67
The organizing committee also called for “an ongoing
international forum” to address genome-editing governance, which
was launched as the International Commission on Clinical Use of
Heritable Human Genome Editing.68 The Commission released its
report, Heritable Human Genome Editing, at a webinar on
September 3, 2020.69 The members of the Commission stressed
65

Id.
See id. One of the co-authors attended and observed.
67
Statement by the Organizing Committee of the Second International
Summit on Human Genome Editing, NAT’L ACADS. SCI., ENG’G, & MED.
(Nov. 28, 2018), https://www.nationalacademies.org/news/2018/11/statementby-the-organizing-committee-of-the-second-international-summit-on-human-genomeediting#:~:text=to%20main%20content-,Statement%20by%20the%20Organizing%20
Committee%20of%20the,Summit%20on%20Human%20Genome%20Editing&text=
The%20committee%20also%20stated%20that,germline%22%20editing%20at%20tha
t%20time [https://perma.cc/QKD8-TFDE].
68
Id.; see International Commission on Clinical Use of Human Germline
Genome Editing, NAT’L ACADS. OF SCI., ENG’G, & MED, http://www.nationalacademi
es.org/gene-editing/international-commission/index.htm?_ga=2.267074126.19190164
42.1562599670-715002107.1562599670 [https://perma.cc/E3CF-FKTD] (last visited
Sept. 25, 2020).
69
NAT’L ACADS. OF SCI., REPORT SUMMARY: HERITABLE HUMAN GENOME
EDITING (2020), https://www.nap.edu/resource/25665/Heritable%20Human%20Geno
me%20Editing%20Report%20Summary%20-%20FINAL%2020200903.pdf
[https://perma.cc/96TK-PSLJ]. The webinar is available at the International
Commission on the Clinical Use of Human Germline Genome Editing webpage.
International Commission on Clinical Use of Human Germline Genome Editing,
NAT’L ACADS. OF SCI., ENG’G & MED., https://www.nationalacademies.org/ourwork/international-commission-on-the-clinical-use-of-human-germline-genome66
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that no applications should be undertaken until scientists can
“efficiently and reliably” edit human embryos without off-target
effects, and that science is not yet at that point.70 Looking ahead,
the Commission members proposed a ranking system for potential
uses, with the highest priority being serious monogenic (caused by
a single gene) conditions for people who could not have a healthy
biological child through current embryo selection technology and
the lowest being enhancement addressed to non-disease traits,
using HIV resistance as an example. Although the report offers
recommendations for a “translational pathway” to heritable human
genome editing (“HHGE”) that have significant legislative and
regulatory implications for both nations and international bodies,
the International Commission is at pains to present itself as
primarily an exercise in professional self-governance by the
scientific community.71 As the report says, while “the decision to
permit the clinical use of HHGE and, if so, for which specific
applications, must ultimately rest with individual countries
following informed societal debate of both ethical and scientific
considerations,” the goal is “to elaborate national and international
mechanisms necessary for appropriate scientific governance of
HHGE, while recognizing that additional governance mechanisms
may be needed to address societal considerations that lie beyond
the Commission’s charge.”72
B. Hopes and Fears for Hard Approaches to International
Governance
There is currently no international hard (imposed by
governments and having the force of law) regulation of human
genome editing or its medical applications.73 One organization that
editing (last visited Nov. 16, 2020). Some of the co-authors attended the
webinar.
70
NAT’L ACADS. OF SCI., REPORT SUMMARY: HERITABLE HUMAN GENOME
EDITING, supra note 69, at 3.
71
Id. at 1–2.
72
Id.
73
For a survey of the regulatory landscape, see R. Alta Charo, The Legal and
Regulatory Context for Human Gene Editing, ISSUES SCI. & TECH.,
https://issues.org/the-legal-and-regulatory-context-for-human-gene-editing/
[https://perma.cc/FY2P-D79Y].
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has advocated an international law approach is ARRIGE,
mentioned above.74 ARRIGE is a nongovernmental organization
founded in France in 2018 whose objectives include “promot[ing]
a global governance of genome editing through a comprehensive
setting for all stakeholders” and “foster[ing] the development of
genome editing technologies within a safe and ethical
framework.”75 It has also advocated an international law approach.
In December 2018, ARRIGE proposed:
[T]he modification of any UNESCO universal declarations, such as the
Declaration on the Human Genome, to include a simple additional
point clearly stating that the application of human genome edited
technologies should not be permitted nor authorized until deemed safe
and effective for human beings, with precise therapeutic applications
justified after a broad and open debate.76

In a comparable but narrower initiative, a group of fifteen
individual international researchers argued for a moratorium on
germline genome editing in Nature in March 2019, calling “for the
establishment of an international framework in which nations,
while retaining the right to make their own decisions, voluntarily
commit to not approve any use of clinical germline editing unless
certain conditions are met.”77
Another initiative that may point in the direction of harder
forms of governance at the international level is the aspiration of
the Expert Advisory Committee of the World Health Organization
to develop global standards for governance of genome editing that
could ultimately be turned into law. In 2019, the Expert Committee
proposed a central, worldwide registry of ongoing human genome

74

About Us, ASS’N FOR RESPONSIBLE RSCH. & INNOVATION IN GENOME EDITING,
https://arrige.org/aboutus.php [https://perma.cc/H3DD-7APS].
75
Id.
76
ASS’N FOR RESPONSIBLE RSCH. & INNOVATION IN GENOME EDITING, STATEMENT
FROM ARRIGE STEERING COMMITTEE ON THE POSSIBLE FIRST GENE-EDITED
BABIES (Dec. 3, 2018), https://arrige.org/ARRIGE_statement_geneeditedbabies.pdf
[https://perma.cc/Z69V-VQZ3]. ARRIGE’s current president, Lluis Montoliu, has
recently elaborated on this position. See infra note 91 and accompanying text.
77
Eric Lander et al., Adopt A Moratorium on Heritable Genome Editing, 567
NATURE 165, 165 (2019), https://media.nature.com/original/magazine-assets/d41586019-00726-5/d41586-019-00726-5.pdf [https://perma.cc/7LCH-M47P].
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editing research.78 But, more recently, the Expert Committee has
published a draft framework for governance.79 As the Authors will
discuss below, the draft has turned toward a new governance
approach that includes an array of governmental and
nongovernmental stakeholders.80
Given the difficulties of developing and implementing hard
governance approaches at the international level, some
country-based policy efforts have focused on articulating hard
rules at the national level. In the United States, much of the
discussion on new hard regulatory approaches to genome editing
has been driven by NASEM, a co-sponsor of the 2018 Hong Kong
conference discussed above.81 Although the National Academies
are private nonprofit organizations, they date back to a
congressional charter signed by Abraham Lincoln and are in that
sense government-related public organizations. In its 2017 report,
Human Genome Editing: Science, Ethics, and Governance,
NASEM recommended that existing regulatory processes be
applied to basic laboratory research and to somatic human genome
editing to treat or prevent disease or disability.82 It further
recommended against permitting human genome editing for
enhancement purposes, defined as “purposes other than treatment
or prevention of disease and disability.”83 Finally, NASEM
recommended that clinical trials of germline gene editing be
permitted, but “limited to only the most compelling circumstances
78
WHO Expert Panel Paves Way for Strong International Governance on
Human Genome Editing, WORLD HEALTH ORG. (Mar. 19, 2019),
https://www.who.int/news-room/detail/19-03-2019-who-expert-panel-pavesway-for-strong-international-governance-on-human-genome-editing
[https://perma.cc/6FDS-TCET].
79
Expert Advisory Comm. on Developing Glob. Standards for Governance
and Oversight of Hum. Genome Editing, Human Genome Editing: A DRAFT
Framework for Governance, WORLD HEALTH ORG. 1 (Jan. 2020),
https://www.who.int/ethics/topics/human-genome-editing/Governanceframework-for-HGE-Jan2020.pdf?ua=1 [https://perma.cc/NWX4-AQT6].
80
See infra notes 128–30 and accompanying text.
81
See supra notes 64–66 and accompanying text.
82
NAT’L ACADS. OF SCI., ENG’G, & MED., HUMAN GENOME EDITING: SCIENCE,
ETHICS, AND GOVERNANCE 185 (2017). For a regulatory survey, see Brokowski, supra
note 1, at 116–20.
83
NAT’L ACADS. OF SCI., ENG’G, & MED., supra note 82, at 192.

DEC. 2020]

Regulating Human Genome Editing

127

and subject to a comprehensive oversight framework.”84 that
satisfies ten rigorous criteria.85 Immediate reactions to the report
focused on this final recommendation, which one journalist
characterized as a “yellow light to human embryo editing.”86
Conferences representing the broader scientific community
reflect a more skeptical view of top-down governance, with
governmental authorities imposing binding rules. For example, at
the 2018 CRISPRcon conference (which members of the research
group attended), where “a broad selection of diverse voices [came]
together to discuss the future of CRISPR and related gene editing,”87
real-time audience polling indicated that the audience viewed
international regulation (presumably of the hard variety) of
germline editing as having high importance but low feasibility.
Various speakers emphasized the difficulties of making and
enforcing treaties and the fragmentary, often ill-suited nature of
existing national regulations; instead, many stressed local
regulation, voluntary attention to local communities, and scientific
guidelines. A significant theme was the danger of regulatory
arbitrage: in a world that relies on government regulation, risky
research will seek out the least-regulated environment—at the
moment, China.88
At the 2018 Genome Writers Guild conference,89 project
members in attendance heard a speaker argue that “regulation will
84

Id. at 189.
Id. at 189–90.
86
Jocelyn Kaiser, U.S. Panel Gives Yellow Light to Human Embryo Editing,
SCI. MAG. (Feb. 14, 2017, 11:00 AM), https://www.sciencemag.org/news/2017/02/uspanel-gives-yellow-light-human-embryo-editing [https://perma.cc/36Z5-KWDG].
87
CRISPRCON, https://crisprcon.org/crisprcon-2018/ [https://perma.cc/85PSCQW3] (last visited Sept. 25, 2020).
88
Recent Events Highlight an Unpleasant Scientific Practice: Ethics
Dumping, ECONOMIST (Feb. 2, 2019), https://www.economist.com/science-andtechnology/2019/02/02/recent-events-highlight-an-unpleasant-scientificpractice-ethics-dumping [https://perma.cc/6UZV-6BAG].
89
GWG
2018
Conference,
GENOME
WRITERS
GUILD,
https://www.genomewritersguild.org/gwg-2018-conference [https://perma.cc/ZX7BLBNU] (last visited Sept. 8, 2020). Here and elsewhere, unless otherwise
indicated (such as where presentations were recorded and are available online),
quotes from speakers at conferences that members of the research group
attended are taken from the researchers’ notes.
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drive creative people underground.” Another suggested that efforts
to increase consumer confidence in genome editing might lead to
“reducing regulatory barriers.” At the same conference in 2020,
speakers continued the theme that research might gravitate toward
countries with minimal regulation. Lluis Montoliu, the current
president of ARRIGE, stated that in the European Union (“EU”),
“unfortunately,” edited organisms are treated as genetically
modified organisms (“GMOs”) and are thus presumptively
forbidden; with “progress blocked” in the EU, research goes
elsewhere.90 In a different vein, at the 2020 World Congress of
Bioethics, a bioethicist from the National University of Singapore
noted that lax regulation can lead to gene editing “tourism.”91
Consequently, he stressed, there is a strong need for global
governance to overcome narrow national interests. Nonetheless,
“national interest can be leveraged in global governance”—being
saddled with a “rogue” reputation can be a meaningful sanction, as
China has learned from the He experiments.92
C. New Governance and Public Trust
A third dominating theme from these early discussions has
been the importance of transparent and publicly engaged
approaches to governance to encourage wider trust in genomic
science. Almost all the major policy declarations, organizational
platforms, and promotional conference rhetoric reflect a deep
concern for public opinion, by advocating increased public
engagement and seeing a need for societal consensus in any
governance development process.93 For example, one of the first
90

Genome Writers Guild, GWGCON2020 Session 7, YOUTUBE (Aug. 11, 2020)
https://www.youtube.com/watch?v=BAG7sTapFUM&list=PLPxVuE44an0BWlc
RT9TbunE2hJ6jOjHIC&index=2 [https://perma.cc/K8R3-W3G7] (broadcasting the
address of Lluis Montoliu, president of ARRIGE, at the 2020 Genome Writers
Guild).
91
G. Owen Schaefer, Sociopolitical Dimensions of Germline Gene Editing, 15TH
WORLD CONGRESS OF BIOETHICS VIRTUAL CONFERENCE, program available at
https://iab2020.org/ [https://perma.cc/D7D4-NTXL] (last visited Sept. 8, 2020).
92
Id.
93
See Eric T. Juengst, Crowdsourcing the Moral Limits of Human Gene
Editing?, 47 HASTINGS CENTER REP. 15, 15–23 (May 24, 2017),
https://pubmed.ncbi.nlm.nih.gov/28543411/ [https://perma.cc/L27N-2Y6G].
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scientific declarations (from 2015) about human genome editing
concludes that it would be “irresponsible to proceed” with
germline or enhancement applications until “there is broad societal
consensus about the appropriateness of the proposed application.”94
And, as co-author Eric Juengst has pointed out about the 2017
NASEM Report:
Fully half of the report’s fourteen formal recommendations reiterate the
need for public dialogue to drive the policy making process, using a
family of phrases variously calling for “broad,” “extensive,”
“inclusive,” “transparent,” “meaningful,” “expanded,” “robust,” and
“ongoing” public “communication,” “discussion,” “debate,”
“engagement,” “input” and “participation,” as a “necessary condition
for moving forward” before “any consideration of whether to authorize
clinical trials” of either enhancing or inheritable human gene editing
interventions. 95

But others caution that public engagement may not help
advance the goal of more harmonized and publicly trustworthy
governance, especially internationally, because of the dramatic
range of public views about the ethics of genome editing.96 This
diversity of voices and viewpoints was on display at the 2018
CRISPRcon conference, where the moderator of a panel of
activists representing indigenous, disability, agricultural, and other
constituencies concluded, “we may never reach something that is a
consensus. It will fail to satisfy virtually everyone.”97 In a similar
vein, at the 2020 Genome Writer’s Guild Conference, Lluis
Montoliu, the president of ARRIGE, spoke pointedly about the
need “to foster public trust and prove we deserve it.”98 Noting
ARRIGE’s position regarding CRISPR, he counseled attendees to
be honest about its current limitations and to be clear with the
public about off-target effects (accidentally editing the wrong
gene) and heritability concerns.99 He said—perhaps with
94

Lander et al., supra note 77, at 166.
Juengst, supra note 93, at 16 (quoting NAT’L ACADS. OF SCI., ENG’G, &
MED., supra note 82, passim).
96
See id. at 19.
97
See CRISPRcon, CRISPRcon 2018 – Whats at Stake?, YOUTUBE (June 29,
2018), https://www.youtube.com/watch?v=653sn_AmFz0&feature=emb_title
[https://https://perma.cc/G2GT-27WT].
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Genome Writers Guild, supra note 90.
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unintended irony, given science’s mixed messages during the
pandemic—that COVID presents an opportunity to “remind
society that science has procedures, that we have timelines, that we
have permissions, and that we have protocols. That we need to do
one step after the other.”100
At the 2020 World Congress of Bioethics, a bioethicist from
University of Manchester in the United Kingdom pursued the
problem of public trust from a somewhat different angle.101 Starting
from the “assumption . . . that we need public discourse,” he asked
such questions as: “can we get relevant input,” “what’s relevant,”
“what are relevant publics,” and “how do we get input from
them?”102 He concluded by posing an ultimate dilemma: “what if
the public disagrees with bioethicists in the end?” His answer was
that “bioethicists should show humility—consensus is rare—let the
public decide.”103 But he left unaddressed the problem he started
with—discerning the public’s will.104
Another related set of concerns about public trust emerged in a
panel discussion entitled “CRISPR and Human Identity:
Governing Germline Gene Editing” at the 2020 ELSI [referring to
the Ethical, Legal, and Social Implications of genetics] Virtual
Forum.105 A recurrent theme was the need for humility in dealing
with the public. One panelist, Emory University disability scholar
Rosemarie Garland-Thomson, warned of “velvet eugenics.” In
contrast, she urged, the gene editing community needs to “cultivate
an attitude of humility” toward others’ lives and avoid
characterizing mere human variation as “new disease” that gene

100

Id.
Søren Holm, Sociopolitical Dimensions of Germline Gene Editing, 15TH
WORLD CONGRESS OF BIOETHICS VIRTUAL CONFERENCE, program available at
https://iab2020.org/ [https://perma.cc/EFY5-EMXV] (last visited Sept. 8, 2020).
102
Id.
103
Id.
104
Id.
105
ELSI Virtual Forum Video Recordings, COLUM. U. DEP’T MED. HUMS. &
ETHICS, https://www.mhe.cuimc.columbia.edu/our-divisions/division-ethics/elsi
-virtual-forum/elsi-virtual-forum-video-recordings [https://perma.cc/46FP-P5M2]
(last visited Sept. 8, 2020).
101

DEC. 2020]

Regulating Human Genome Editing

131

editing can cure.106 To illustrate the point, she said that “we’re
already practicing eugenics . . . routinely in reproductive medicine.
For example, . . . [we’ve] already decided that the human variations,
[like] Down Syndrome, are unacceptable variations and . . . that kind
of person is ‘expendable’ and ‘disposable’ . . . . [W]hat a serious
disease is, what human suffering might be, we need to look at it
quite a bit more closely.”107
VI.

HOW WELL DO THE VARIOUS APPROACHES TO
GOVERNANCE MEET THESE CONCERNS?
In mapping these concerns onto relevant theories of
governance, the researchers can begin to make some observations
about the promise of the various approaches to governance. Table
1 lists five goals that gene-editing stakeholders have begun to
identify as desiderata that any effective governance regime should
promote: scientific autonomy, international harmonization, and
public trust, plus meaningful enforcement and ease of
implementation. The table then rates each of four potential
approaches to governance—professional self-governance, national
laws, international treaty, and new governance—according to its
apparent capacity to promote these objectives.
A. Scientific Self-Regulation
The potential efficacy of scientific self-regulation is largely a
function of the details of the model chosen. Self-regulation that
depends solely on voluntary compliance with ethical precepts is
only as effective as participants choose to make it. At the other end
of the spectrum, as in the case of law, it can take on many of the
attributes of hard regulation if a government defines the profession
and delegates to it the power to limit entry, police members’
conduct, and expel those who fail to comply with its rules. In the
middle ground, a professional group can informally regulate conduct
through such measures as public shaming (censure) and, in the
106

Rosemarie Garland-Thomson et al., CRSPR and Human Identity:
Governing Germline Gene Editing, ELSI VIRTUAL FORUM (June 16, 2020),
https://www.mhe.cuimc.columbia.edu/our-divisions/division-ethics/elsi-virtualforum/elsi-virtual-forum-video-recordings [https://perma.cc/46FP-P5M2].
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academic world, conditioning publication on ethical warranties.108
This begins to look like a new governance environment, as will be
discussed shortly.
Voluntary professional self-governance obviously maximizes
scientists’ autonomy and control over the scientific enterprise, and
equally obviously does not have sharp teeth. As the model moves
in the direction of the harder regulation of the traditional
professions, the teeth get sharper, but at the expense of autonomy.
International harmonization of voluntary standards is possible, but
meaningless without international enforcement mechanisms.
Public trust is unlikely to be affected by the mere presence of
standards but will depend on how well the scientists behave. Since
self-governance is so open-ended, it can be easy to implement. A
problem with this approach, however, is that “science” has no clear
definition as a profession; the disparate putative members include
researchers from many disciplines as well as healthcare
practitioners who may already be subject to hard regulation.
B. Hard Regulation
Hard regulation on a country-by-country basis has the virtue of
strong enforcement potential, and the adoption of rigorous
standards that are diligently enforced may engender public trust—
or cynicism if enforcement seems lax. But regulations take time
and political will to adopt, and international consistency is unlikely
on any complex legal issue. Moreover, countries may be tempted
to adopt weaker standards to attract research, much like countries
have used weaker environmental and labor standards to attract
industry.109

108

The death of research subject Jesse Gelsinger in a trial employing gene
therapy, a predecessor to gene editing and still in trials today, provides an
example where censure and conditions on publication were imposed as sanctions
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Binding and enforceable international legal regimes—which
solve the harmonization problem—are even more difficult to create
and maintain. First, all the relevant countries—in the gene editing
context, the United States, China, and the EU, at a bare
minimum—must negotiate and sign a treaty. Then each signatory
must ratify the treaty according to its national law. In some cases,
signatory countries must enact national legislation to implement
the treaty.110 Finally, and critically, the signatories must actually
carry out the enforcement they have promised. The recent U.S.
withdrawal from the Paris Agreement on climate change illustrates
these difficulties.111 The Obama administration signed the
Agreement but never submitted it to the U.S. Senate for ratification
as a treaty; the Trump administration therefore treated it as a
non-binding commitment that it was free to repudiate.112 Given all
these obstacles, a meaningful international law of gene editing
seems unlikely for the foreseeable future.
The version of this approach suggested in the Nature proposal
described above113—parallel legal action by individual countries—
avoids some of the formal steps required by the NASEM
Commission report, Heritable Human Genome Editing, with its
recommendation of nation-level action guided by its “translational
pathway.”114 Leaders of essential countries must come to an
agreement on general principles and the manner of implementation,
110
Treaties that require implementing legislation are called non-self-executing
treaties, in contrast to self-executing treaties, which do not. See Self Executing
Treaties, LEGAL INFO. INST., https://www.law.cornell.edu/wex/self_executing_tr
eaty#:~:text=A%20self%2Dexecuting%20treaty%20is,through%20the%20impl
ementation%20of%20legislation [https://perma.cc/D88V-UXBS] (last visited Sept.
25, 2020).
111
See Press Statement, Sec’y of State Michael R. Pompeo, On the U.S.
Withdrawal from the Paris Agreement (Nov. 4, 2019) (on file with the U.S.
Dept. of State).
112
See Eugene Kontrovich, The U.S. Can’t Quit the Paris Climate
Agreement, because It Never Actually Joined, W ASH. POST (June 1, 2017),
https://www.washingtonpost.com/news/volokh-conspiracy/wp/2017/06/01/theu-s-cant-quit-the-paris-climate-agreement-because-it-never-actually-joined/
[https://perma.cc/3ZW9-ZSKF].
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See Lander et al., supra note 77 and accompanying text.
114
See NAT’L ACADS. OF SCI., REPORT SUMMARY, supra note 69.
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and then—at least in democracies—persuade potentially fractious
lawmakers to go along.
C. New Governance
This leaves the hybrid approach that combines aspects of
self-governance with elements of harder regulation. The
still-nebulous proposals for a hybrid approach to governance that the
project has encountered can be grouped under the broad heading of
new governance.115 According to new governance theory, the
democratic state is in the midst of a shift to a “post-regulatory”
model characterized by a weakening of top-down regulation by the
all-powerful administrative state—“old” governance—in favor of a
diffusion of rights and responsibilities among governments, private
companies, NGOs, and other interested parties.116 New governance
approaches involve “transnational private regulation” by coalitions
of non-state actors.117 The essence of the post-regulatory state,
captured in the linguistic shift from government to governance, is
the distribution of regulatory power among transnational networks
of state and non-state actors that often use market and other private
forces to set and enforce standards.118

115

Recent articles have reviewed new governance theory in a variety of
contexts. See, e.g., John Gerard Ruggie, Global Governance and “New
Governance Theory”: Lessons from Business and Human Rights, 20 GLOB.
GOVERNANCE 5 (2014); Myrisha S. Lewis, Innovating Federalism in the Life
Sciences, 92 TEMP. L. REV. 383 (2020); Melanie Hess, A Call for an International
Governance Framework for Human Germline Gene Editing, 95 NOTRE DAME L.
REV. 1369 (2020); Ryan Hagemann, Jennifer Huddleston Skees & Adam Thierer,
Soft Law for Hard Problems: The Governance of Emerging Technologies in an
Uncertain Future, 17 COLO. TECH. L.J. 37 (2018); Jonas J. Monast, Editing
Nature: Reconceptualizing Biotechnology Governance, 59 B.C. L. REV. 2377
(2018).
116
See John M. Conley & Cynthia A. Williams, Engage, Embed, and Embellish:
Theory versus Practice in the Corporate Social Responsibility Movement, 31 J.
CORP. L. 1, 6, 31–33 (2005) (defining attributes of new governance).
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Tim Bartley, Institutional Emergence in an Era of Globalization: The Rise
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113 AM. J. SOCIO. 297, 297 (2007).
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See Conley & Williams, Engage, Embed, and Embellish, supra note 116,
at 31.
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There have been extensive studies of new governance
approaches in other areas that are analogous in important respects
to gene editing research. One example is the corporate social
responsibility movement.119 In that instance, many corporations
have sought to address social and environmental issues by such
strategies as voluntary commitments to industry codes and best
practice standards, convening multi-stakeholder advisory groups
(sometimes adding such constituencies to their boards of directors),
and measuring and disclosing social and environmental risks
through triple bottom line (financial, social, and environmental)
accounting.120 Such private governance networks sometimes adopt
substantive standards promulgated by governmental and
quasi-governmental bodies. For example, the biggest global banks
collectively adopted the World Bank’s social and environmental
standards in establishing the “Equator Principles” to govern private
lending for large-scale projects in developing countries.121
Motivations for participating in new governance regimes can
vary.122 Private actors may perceive a hard regulation vacuum and
move to fill it in the sincere belief that standards must be set. But
they may also see an opportunity to preempt more onerous
governmental regulation by demonstrating, at least superficially,
that they have the problem under control. With respect to efficacy,
new governance advocates sometimes contend that actors who
invest in the creation of standards are more likely to comply than
those who have standards imposed on them. Especially where
science, technology, and other arcane practices are involved,
private actors can plausibly contend that those who know the

119

See generally id.; John M. Conley, Cynthia A. Williams, Lodewijk
Smeehuijzen & Deborah E. Rupp, Can Soft Regulation Prevent Financial
Crises?: The Dutch Central Bank’s Supervision of Behavior and Culture, 51
CORNELL INT’L L.J. 773 (2019) (both sources explaining and illustrating
corporate social responsibility movement).
120
See Conley & Williams, Engage, Embed, and Embellish, supra note 116,
at 2–5.
121
See generally Conley & Williams, Global Banks as Global Regulators,
supra note 8 (providing analysis of adoption of Equator Principles).
122
See id. at 558–62 (reviewing evidence for many of these motives in the
banking context).
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practice best are most qualified to set the standards.123 But it is also
possible that the outcome will be mere window dressing—weak
and easily evaded standards that can nonetheless be sold to
lawmakers and other relevant audiences.124 Likewise, meaningful
enforcement mechanisms can also be difficult to construct in the
absence of governmental authority.125 A central tenet of the
corporate social responsibility movement, for example, is that
investors and consumers, informed by adverse publicity and triple
bottom line reporting, will become aware of noncompliance and
penalize laggards. But the evidence for this “business case” for
compliance is inconclusive; it is unclear whether either profits or
share performance correlate with indicators of social responsibility.126
One can readily envision such a governance network arising
with respect to CRISPR genome editing—indeed, the project may
be witnessing its formative stages. Even in the absence of hard
regulations, governmental authorities may play a role, perhaps by
the promulgation of standards as ARRIGE has suggested.127 The
early evidence suggests that other key actors are likely to be
scientists; NGOs; interested for-profit corporations and their
principals; scientific gatekeepers including funders, journal editors,
university officials, and voluntary scientific organizations; and
organized voices speaking for affected communities and other
public constituencies.128
123
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Depending on the actor, motivations to participate may include
professionalism, ethics, principle, profit, self-promotion, and
ideology; their respective contributions to the ultimate mix will
strongly influence the quality of any standards that result. Scientific
stakeholders may be best positioned to resolve thorny definitional
questions such as distinguishing treatment and prevention from
enhancement. Even in the absence of governmental sanctions,
meaningful enforcement mechanisms could include access to
funding and publication; academic hiring and promotion decisions;
exclusion from important organizations; and, at the most basic
human level, shame and obloquy versus honor and prestige. While
these carrots and sticks can be significant, they fall short of the
civil and criminal penalties that governments can exact.
There is growing evidence from the research to date that a range
of gene editing stakeholders are already gravitating toward the new
governance approach. The most significant piece of evidence is the
World Health Organization’s Expert Advisory Committee’s recently
issued draft report.129 The report’s lengthy definition of “good
governance” is in fact a comprehensive definition of new governance:
Good governance is not limited to formal regulation pursuant to
legislation or judicial opinion. Governance is a system of norms as well
as influence, and it includes forces to shape the direction and conditions
of research and applications, such as well-crafted public and private
funding priorities and conditions. Good governance also includes
professional and industrial best practices, peer review and ethics
assurance by publishers, and health care insurance coverage decisions
for instance. Possible liability for harmful research or clinical care is an
indirect source of governance, mediated by liability insurance.130

technologies, questions in defining “emerging biotechnologies,” and
concerns about proper stakeholder engagement. See Carrie D. Wolinez,
Introducing the NExTRAC, NAT’L INST. HEALTH (April 24, 2019),
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Similarly, its list of “tools for governance” enumerates all the
possible mechanisms for shaping behavior that new governance
theorists have envisioned:
Tools for Governance:
• Law: Declarations, Treaties, Conventions, Legislation,
Regulation
• Judicial rulings
• Ministerial decrees
• Conditions on research funding
• Moratoria
• Accreditation, registration, licensing
• Professional self-regulation
• Research ethics guidelines
• Collaboration with publishers and conference organizers
• Education and training of researchers and
clinician-scientists
• Interest groups and public influencers131
A second recent example comes from the 2020 Genome
Writers Guild Conference. A representative from the U.S. National
Institute of Standards and Technology (“NIST”) emphasized the
government’s interest in a new governance approach to gene
editing.132 As its name suggests, NIST, which is part of the U.S.
Department of Commerce, works with the academic and private
sectors “[t]o promote U.S. innovation and industrial
competitiveness by advancing measurement science, standards,
and technology in ways that enhance economic security and
improve our quality of life.”133 Importantly, it is not a regulatory
agency.
131

Id.
See Genome Writers Guild, supra note 90 (broadcasting the address of
Samantha Maragh titled “A Consortium Approach to Foster Confidence in Gene
Editing” beginning at 24:17).
133
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Samantha Maragh, the Leader of NIST’s Genome Editing
Program,134 speaking on a panel with the odd title of “EU Regulatory
Landscape – genome engineering and supporting the public trust,”135
gave a presentation entitled “A Consortium approach to foster
confidence in genome editing technology.”136 The consortium that
NIST is sponsoring is a public-private collaboration, currently
including thirty-seven organizations from government (most
prominently, the USFDA), industry, academic science, and the
non-profit sector. Its purpose, Maragh said, “meant to be enabling,
not limiting”—specifically, its goal should be the advancement of
gene editing technology.137 One might question whether
“foster[ing] confidence” is anything more than a public relations
objective or whether confidence, as opposed to safety, is an
appropriate concern for a standard-setting body, as well as the
absence of public voices from the consortium. But there is no
doubt that Maragh was describing a new governance network not
fundamentally different from the Equator Principles signatories.
One reason that a new governance approach is being endorsed
for gene editing research is that it can be much easier to implement
than more traditional regulatory approaches, especially at the
international level. As the speed with which the Equator Principles
were adopted illustrates,138 professional and other private
stakeholders can move quickly, and on a global scale. In every
other category, however, the promise of a new governance
approach to gene editing research is equivocal. If done well, it can
certainly promote public trust, work consistently across
international boundaries, and result in meaningful enforcement.
Because scientists would be critical stakeholders, the categories are
interrelated: success in one depends on corresponding success in
134

Genome Writers Guild, supra note 132.
In the first place, it is unclear what it means to “support” public trust unless
the trust is already there. In any event, none of the six speakers said anything
about public trust.
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the others. Thus, scientists can retain their autonomy and create
public trust only by promoting strong standards and submitting to
rigorous enforcement. The Equator Principles experience is again
relevant here. It is unclear whether they really have reduced the
adverse social and environmental impacts of large-scale projects.139
There is widespread agreement that the participating banks have
done a reasonably diligent job of monitoring their borrowers, but
equally widespread concern that the adoption of the Principles may
have driven some project sponsors to seek out non-participating
lenders in Russia, China, and elsewhere.140 But despite this mixed
evidence, new governance is the only approach with realistic
potential to promote each of the objectives identified in Table 1 in
the short to medium term.
Table 1: Evaluating Approaches to Governance
Priorities

International
Treaty

National
Laws

Professional
SelfGovernance

New
Governance

Scientific
Control

–

–

+

+/–

Regulatory
Teeth

+

+

–

+/–

International
Harmonization

+

–

–

+/–

Public Trust

+

+/–

–

+/–

Ease of
Implementation

–

–

+/–

+

Summary of the different approaches to governance and the ability of each to promote
the enumerated priorities.

VII. CONCLUSION
As the embryo experiments in China illustrate, the early
implementation of human genome editing has had a
“ready-fire-aim” quality. Scientific self-regulation has not been
able to anticipate events well enough to secure widespread
139
140

See id. at 562–64 (reviewing inconclusive evidence).
See id. at 566–67.
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international allegiance to common standards and has thus been
relegated to clean-up responses in the wake of scandal. Regulation
by international law is a long and contested process at best; the
complexities of human genome editing only lengthen the odds
against such a solution. Negotiating and implementing consistent
nation-by-nation regulations is not much easier. This may be a
situation where a hybrid new governance approach, despite its
inevitable shortcomings, will be far preferable to the chaos of no
meaningful governance at all. Early evidence suggests that the
scientific community and its various constituencies are heading in
this direction, with constant attention to public engagement along
the way. Given the potential costs of doing nothing, these are
developments that the Authors encourage despite their
shortcomings.

142

N.C. J.L. & TECH.

[VOL. 22: 2

